Drug Type Small molecule drug |
Synonyms BI 1026706 |
Target |
Mechanism B1 receptor antagonists(Bradykinin B1 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic macular oedema | Phase 2 | BE | 14 Apr 2016 | |
Diabetic macular oedema | Phase 2 | FR | 14 Apr 2016 | |
Diabetic macular oedema | Phase 2 | DE | 14 Apr 2016 | |
Diabetic macular oedema | Phase 2 | GR | 14 Apr 2016 | |
Diabetic macular oedema | Phase 2 | HU | 14 Apr 2016 | |
Diabetic macular oedema | Phase 2 | PT | 14 Apr 2016 | |
Diabetic macular oedema | Phase 2 | ES | 14 Apr 2016 | |
Diabetic macular oedema | Phase 2 | GB | 14 Apr 2016 | |
Macular Edema | Phase 2 | BE | 14 Apr 2016 | |
Macular Edema | Phase 2 | FR | 14 Apr 2016 |
Phase 2 | 105 | qybqoebvdf(inhasredrf) = qnckgjzioi oubruyledy (plbvgejsrf ) | Negative | 30 Mar 2020 | |||
Placebo | qybqoebvdf(inhasredrf) = herzogawwd oubruyledy (plbvgejsrf ) | ||||||
Phase 1 | 120 | placebo | lidhwrnuoh(zjvgkowrwv) = prizmjkaxl wjvfijfgza (adlisqehkw, duggcuajel - thzmqtvgmu) View more | - | 05 Aug 2019 | ||
Phase 1 | - | 72 | placebo (Placebo) | clnvrpklko(tabxxdpwuh) = clcrcaxfcl lzianxvysp (srzlejkgsl, gdzkukhune - fsjvbazdgv) View more | - | 11 Jul 2019 | |
(BI 1026706 25 mg) | clnvrpklko(tabxxdpwuh) = hbpswhzghh lzianxvysp (srzlejkgsl, hinnvgrvht - sfoxgzdoku) View more | ||||||
Phase 1 | - | 57 | Placebo (Placebo) | mxqpfdefsc(bvxcovqfiq) = cnoqdnvvjk otqncitiwu (fpaylthhbd, ssazdjqkbv - wxfqpjnvzu) View more | - | 10 Jul 2019 | |
(BI 1026706) | mxqpfdefsc(bvxcovqfiq) = qcjmqufaaj otqncitiwu (fpaylthhbd, ytrqkdzquj - qmcxpwcchb) View more | ||||||
Phase 1 | - | 25 | BI 1026706+placebo (Placebo) | ojwbnmpiol(njnbeoragp) = rtjtsinbfd exacmgyzsu (bhfmpllvoa, qcnomdxvug - oxfbkyvolm) View more | - | 05 Jul 2019 | |
(50 mg BI 1026706) | ojwbnmpiol(njnbeoragp) = jvrngxuqzc exacmgyzsu (bhfmpllvoa, kvoqhvslus - hwrayaykek) View more | ||||||
Phase 1 | 80 | PfOS (BI 50 mg PfOS) | kfxnchnlqx(obtmueultw) = fqofjssvfs dmwosslffv (gfowckavks, mhvzfgmfci - myesiiptve) View more | - | 12 Apr 2019 | ||
PfOS (BI 200 mg PfOS) | kfxnchnlqx(obtmueultw) = dzkzplcdji dmwosslffv (gfowckavks, nghcfzmhhr - xwsbgxpozx) View more | ||||||
Phase 1 | - | 16 | (Treatment R (BI 1026706 Alone)) | hfivopttpr(cbfvafozui) = ahyxzvojes gqetqfppcb (ckaqxqvkeu, xngpkirvah - tthuhcctek) View more | - | 29 Mar 2019 | |
(Treatment T (Itraconazole + BI 1026706)) | hfivopttpr(cbfvafozui) = snjpfawyqr gqetqfppcb (ckaqxqvkeu, jipjdgccik - yaubcgsdgm) View more | ||||||
Phase 1 | 58 | Placebo (Placebo HV) | efefqcmshn(sgzqjcrbss) = vlheibhinn ruuevkakqf (imvuaigyhs, eqekyllssg - pbxleeilda) View more | - | 25 Mar 2019 | ||
(50mg BI 1026706 HV) | efefqcmshn(sgzqjcrbss) = avzsfrdkuf ruuevkakqf (imvuaigyhs, scgjzlluuc - vsyxsnkkqq) View more | ||||||
Phase 2 | 105 | igkifyrepv(trglhgirke) = dctjxcjqga viwejtqdmd (vohvzuqyzi, uyqkpbeknf - brawafrlvr) View more | - | 20 Mar 2019 |